Journal List > J Korean Orthop Assoc > v.40(5) > 1012426

TOOLS
Kim, Kim, Park, Kim, and Lee: Effects of the Peroxisome Proliferator-Activated Receptor Ligand Troglitazone in Osteosarcoma Cell Lines
Original Article

Journal of the Korean Orthopaedic Association 2005; 40(5): 591-597.

Published online: 28 December 2017

DOI: https://doi.org/10.4055/jkoa.2005.40.5.591

Effects of the Peroxisome Proliferator-Activated Receptor Ligand Troglitazone in Osteosarcoma Cell Lines

Yeung Jin Kim, Tae Kyun Kim, Jin Young Park, Hyoung Joon Kim, Ji Wan Lee

Department of Orthopedic Surgery, College of Medicine, Wonkwang University Hospital, Iksan, Korea.

yjkim1@wonkwang.ac.kr

Copyright © 2005 The Korean Orthopaedic Association

Abstract

Purpose

We wanted to investigate the effects of Troglitazone (TRO) on the cellular growth in two human osteosarcoma cell lines (U2OS and HOS).

Materials and Methods

Cell viability was assessed by performing trypan blue exclusion assay. FACScan analysis was performed to study the cell cycle and apoptosis. Antibodies against PTEN, tAkt, pAKt, Bcl-2, Bax, pRB, p21(Cip1), and beta-actin were used in the Western blot analysis.

Results

TRO inhibited the growth of both the osteosarcoma cell lines. TRO induced G0/G1 arrest in the cell cycle progression for both osteosarcoma cell lines. TRO induced the apoptosis of HOS cells, but it decreased apoptosis of the U2OS cells. TRO induced Rb dephosphorylation and the increased expression of p21(Cip1). TRO increased the PTEN and Bcl-2 expressions and it decreased the level of pAkt, pRb and Bax.

Conclusion

The present study suggested that TRO may be used as a chemotherapeutic agent for the treatment of human OS. Yet further study is required for uncovering the precise the mechanism of TRO.

Keywords: Osteosarcoma, Troglitazone (TRO)

TOOLS
Similar articles